Skip to main content

Advertisement

SpringerLink
Log in

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases

  • Sleep (M Thorpy and M Billiard Section Editors)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

In patients with neurodegenerative diseases, sleep disorders are common; they impair the quality of life for patients and caregivers and are associated with poorer clinical outcomes. Melatonin has circadian, hypnotic, and free radical-scavenging effects, and preclinical data suggest benefits of melatonin on neurodegeneration. However, randomized, controlled trials of melatonin in patients with neurodegenerative diseases have not shown strong effects. Trials in Alzheimer’s patients demonstrate a lack of benefit on sleep quantity. Subjective measures of sleep quality are mixed, with possible symptomatic improvements seen only on some measures or at some time points. Benefits on cognition have not been observed across several studies. In Parkinson’s patients, there may be minimal benefit on objective sleep measures, but a suggestion of subjective benefit in few, small studies. Effective treatments for the sleep disorders associated with neurodegenerative diseases are urgently needed, but current data are insufficient to establish melatonin as such a treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol. 2009;29:446–67.

    Article  PubMed  Google Scholar 

  2. Raggi A, Ferri R. Sleep disorders in neurodegenerative diseases. Eur J Neurol. 2010;17:1326–38.

    CAS  PubMed  Google Scholar 

  3. Hauw JJ, Hausser-Hauw C, De Girolami U, et al. Neuropathology of sleep disorders: a review. J Neuropathol Exp Neurol. 2011;70:243–52.

    Article  PubMed  Google Scholar 

  4. Naismith SL, Lewis SJ, Rogers NL. Sleep-wake changes and cognition in neurodegenerative disease. Prog Brain Res. 2011;190:21–52.

    Article  PubMed  Google Scholar 

  5. Zhong G, Naismith SL, Rogers NL, et al. Sleep-wake disturbances in common neurodegenerative diseases: a closer look at selected aspects of the neural circuitry. J Neurol Sci. 2011;307:9–14.

    Article  PubMed  Google Scholar 

  6. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007;8 Suppl 4:S27–34.

    Article  PubMed  Google Scholar 

  7. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9:185–200.

    Article  PubMed  Google Scholar 

  8. Bonanni E, Maestri M, Tognoni G, et al. Daytime sleepiness in mild and moderate Alzheimer’s disease and its relationship with cognitive impairment. J Sleep Res. 2005;14:311–7.

    Article  PubMed  Google Scholar 

  9. Khachiyants N, Trinkle D, Son SJ, et al. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011;8:275–87.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bachman D, Rabins P. "Sundowning" and other temporally associated agitation states in dementia patients. Annu Rev Med. 2006;57:499–511.

    Article  CAS  PubMed  Google Scholar 

  11. Gaig C, Iranzo A. Sleep-disordered breathing in neurodegenerative diseases. Curr Neurol Neurosci Rep. 2012;12:205–17.

    Article  PubMed  Google Scholar 

  12. Iranzo A, Comella CL, Santamaria J, et al. Restless legs syndrome in Parkinson’s disease and other neurodegenerative diseases of the central nervous system. Mov Disord. 2007;22 Suppl 18:S424–30.

    Article  PubMed  Google Scholar 

  13. Bliwise DL, Trotti LM, Yesavage JA, et al. Periodic leg movements in sleep in elderly patients with Parkinsonism and Alzheimer’s disease. Eur J Neurol. 2012;19:918–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72:707–12.

    Article  PubMed  Google Scholar 

  15. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.

    Article  PubMed  Google Scholar 

  16. Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris. 2011;105:170–82.

    Article  PubMed  Google Scholar 

  17. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403–19.

    Article  CAS  PubMed  Google Scholar 

  18. Pandi-Perumal SR, BaHammam AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23:267–300. Comprehensive review of melatonin’s anti-oxidant properties and potential utility in neurodegenerative diseases.

    Article  CAS  PubMed  Google Scholar 

  19. Jenwitheesuk A, Nopparat C, Mukda S, et al. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int J Mol Sci. 2014;15:16848–84.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15:385–92.

    Article  PubMed  Google Scholar 

  21. Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (set and reset): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015;386:1754–64.

    Article  CAS  PubMed  Google Scholar 

  22. Alberti S, Chiesa A, Andrisano C, et al. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol. 2015;35:296–303.

    Article  CAS  PubMed  Google Scholar 

  23. Corruble E, de Bodinat C, Belaidi C, et al. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16:2219–34.

    Article  CAS  PubMed  Google Scholar 

  24. Review manager (revman). 5.3 ed. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration; 2014.

  25. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric-disorders—a meta-analysis. Arch Gen Psychiatry. 1992;49:651–68.

    Article  CAS  PubMed  Google Scholar 

  26. Moran M, Lynch CA, Walsh C, et al. Sleep disturbance in mild to moderate Alzheimer’s disease. Sleep Med. 2005;6:347–52.

    Article  PubMed  Google Scholar 

  27. Guarnieri B, Adorni F, Musicco M, et al. Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian clinical cross-sectional study on 431 patients. Dement Geriatr Cogn Disord. 2012;33:50–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.

    Article  PubMed  Google Scholar 

  29. Hatfield CF, Herbert J, van Someren EJW, et al. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer’s dementia. Brain. 2004;127:1061–74.

    Article  CAS  PubMed  Google Scholar 

  30. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.

  31. Cardinali DP, Furio AM, Brusco LI. The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer’s disease. Recent Patents Endocr Metab Immune Drug Discov. 2011;5:80–90.

    Article  CAS  Google Scholar 

  32. Peter-Derex L, Yammine P, Bastuji H, et al. Sleep and Alzheimer’s disease. Sleep Med Rev. 2015;19:29–38. A well-written review of the bidirectional relationships between sleep and AD.

    Article  PubMed  Google Scholar 

  33. Yin Y, Liu Y, Zhuang J, et al. Low-dose atypical antipsychotic risperidone improves the 5-year outcome in Alzheimer’s disease patients with sleep disturbances. Pharmacology. 2015;96:155–62.

    Article  CAS  PubMed  Google Scholar 

  34. Bianchetti A, Scuratti A, Zanetti O, et al. Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after-discharge from an Alzheimer dementia unit. Dementia. 1995;6:108–12.

    CAS  PubMed  Google Scholar 

  35. You SC, Walsh CM, Chiodo LA, et al. Neuropsychiatric symptoms predict functional status in Alzheimer’s disease. J Alzheimers Dis. 2015;48:863–9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Shin HY, Han HJ, Shin DJ, et al. Sleep problems associated with behavioral and psychological symptoms as well as cognitive functions in Alzheimer’s disease. J Clin Neurol. 2014;10:203–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Spalletta G, Long JD, Robinson RG, et al. Longitudinal neuropsychiatric predictors of death in Alzheimer’s disease. J Alzheimers Dis. 2015;48:627–36.

    Article  PubMed  Google Scholar 

  38. Liu RY, Zhou JN, van Heerikhuize J, et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein e-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999;84:323–7.

    CAS  PubMed  Google Scholar 

  39. Duffy JF, Zitting KM, Chinoy ED. Aging and circadian rhythms. Sleep Med Clin. 2015;10:423–34.

    Article  PubMed  Google Scholar 

  40. Mishima K, Tozawa T, Satoh K, et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry. 1999;45:417–21.

    Article  CAS  PubMed  Google Scholar 

  41. Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35:125–30.

    Article  CAS  PubMed  Google Scholar 

  42. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47.

  43. Mahlberg R, Walther S, Kalus P, et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging. 2008;29:203–9.

    Article  CAS  PubMed  Google Scholar 

  44. Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8:623–36.

    Article  PubMed  Google Scholar 

  45. Scullin MK, Bliwise DL. Sleep, cognition, and normal aging: integrating a half century of multidisciplinary research. Perspect Psychol Sci. 2015;10:97–137. Extensive synthesis of relationship between sleep and cognition in young and older adults.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Villa C, Ferini-Strambi L, Combi R. The synergistic relationship between Alzheimer's disease and sleep disorders: An update. J Alzheimers Dis. 2015;46:571–80.

    Article  PubMed  Google Scholar 

  47. Bedrosian TA, Herring KL, Weil ZM, et al. Altered temporal patterns of anxiety in aged and amyloid precursor protein (app) transgenic mice. Proc Natl Acad Sci U S A. 2011;108:11686–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci. 1997;17:1683–90.

    CAS  PubMed  Google Scholar 

  49. Bozner P, Grishko V, LeDoux SP, et al. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol. 1997;56:1356–62.

    Article  CAS  PubMed  Google Scholar 

  50. Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem. 1998;273:7185–8.

    Article  CAS  PubMed  Google Scholar 

  51. Poeggeler B, Miravalle L, Zagorski MG, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein e4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001;40:14995–5001.

    Article  CAS  PubMed  Google Scholar 

  52. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem. 2003;85:1101–8.

    Article  CAS  PubMed  Google Scholar 

  53. Feng Z, Qin C, Chang Y, et al. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med. 2006;40:101–9.

    Article  CAS  PubMed  Google Scholar 

  54. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res. 2009;47:82–96.

    Article  CAS  PubMed  Google Scholar 

  55. Dragicevic N, Copes N, O'Neal-Moffitt G, et al. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res. 2011;51:75–86.

    Article  CAS  PubMed  Google Scholar 

  56. Garcia-Mesa Y, Gimenez-Llort L, Lopez LC, et al. Melatonin plus physical exercise are highly neuroprotective in the 3xtg-ad mouse. Neurobiol Aging. 2012;33(1124):e13–29.

    PubMed  Google Scholar 

  57. Rudnitskaya EA, Muraleva NA, Maksimova KY, et al. Melatonin attenuates memory impairment, amyloid-beta accumulation, and neurodegeneration in a rat model of sporadic Alzheimer's disease. J Alzheimers Dis. 2015;47:103–16.

    Article  CAS  PubMed  Google Scholar 

  58. O'Neal-Moffitt G, Delic V, Bradshaw PC, et al. Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in abetapp(swe)/ps1 mice. Mol Neurodegener. 2015;10:27.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Rosales-Corral S, Tan DX, Reiter RJ, et al. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J Pineal Res. 2003;35:80–4.

    Article  CAS  PubMed  Google Scholar 

  60. Yang X, Yang Y, Fu Z, et al. Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol. 2011;25:1118–25.

    Article  CAS  PubMed  Google Scholar 

  61. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003;26:893–901. A randomized controlled trial of melatonin in neurodegenerative disease.

    PubMed  PubMed Central  Google Scholar 

  62. Dowling GA, Burr RL, Van Someren EJ, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:239–46. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  PubMed  Google Scholar 

  63. Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatr Off J Am Assoc Geriatr Psychiatr. 2009;17:166–9. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  Google Scholar 

  64. Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch = Nippon Ika Daigaku zasshi. 2003;70:334–41. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  PubMed  Google Scholar 

  65. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–61. A randomized controlled trial of melatonin in neurodegenerative disease.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Serfaty M, Kennell-Webb S, Warner J, et al. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatr. 2002;17:1120–7. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  Google Scholar 

  67. Haffmans PM, Sival RC, Lucius SA, et al. Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. Int J Geriatr Psychiatr. 2001;16:106–10. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  CAS  Google Scholar 

  68. Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642–55. A randomized controlled trial of melatonin in neurodegenerative disease.

  69. Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (aswpd), delayed sleep-wake phase disorder (dswpd), non-24-hour sleep-wake rhythm disorder (n24swd), and irregular sleep-wake rhythm disorder (iswrd). An update for 2015: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2015;11:1199–236.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–76.

    Article  CAS  PubMed  Google Scholar 

  71. Barone P, Antonini A, Colosimo C, et al. The priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–9.

    Article  PubMed  Google Scholar 

  72. Suzuki K, Miyamoto M, Miyamoto T, et al. Parkinson’s disease and sleep/wake disturbances. Curr Neurol Neurosci Rep. 2015;15:8.

    Article  PubMed  Google Scholar 

  73. Bliwise DL, Trotti LM, Rye DB. Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In: Watts RL, Standaert DG, Obeso J, editors. Movement disorders. 3rd ed: McGraw-Hill; 2011. p. 935-74.

  74. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71:589–95.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Ratti PL, Negre-Pages L, Perez-Lloret S, et al. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease: insights from a cross-sectional evaluation of the French copark cohort. Parkinsonism Relat Disord. 2015;21:1323–9.

    Article  PubMed  Google Scholar 

  76. Wang P, Wing YK, Xing J, et al. Rapid eye movement sleep behavior disorder in patients with probable alzheimer's disease. Aging Clin Exp Res. 2015.

  77. Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Karlsen KH, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;66:431–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. Predictors and course of health-related quality of life in Parkinson’s disease. Mov Disord. 2008;23:1420–7.

    Article  PubMed  Google Scholar 

  80. Bolitho SJ, Naismith SL, Rajaratnam SM, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15:342–7.

    Article  CAS  PubMed  Google Scholar 

  81. Fertl E, Auff E, Doppelbauer A, et al. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Parkinsons Dis Dement Sect. 1993;5:227–34.

    Article  CAS  Google Scholar 

  82. Videnovic A, Breen DP, Barker RA, et al. The central clock in patients with parkinson disease—reply. JAMA Neurol. 2014;71:1456–7.

    Article  PubMed  Google Scholar 

  83. Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71:463–9.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Mayo JC, Sainz RM, Tan DX, et al. Melatonin and Parkinson’s disease. Endocrine. 2005;27:169–78.

    Article  CAS  PubMed  Google Scholar 

  85. Belaid H, Adrien J, Karachi C, et al. Effect of melatonin on sleep disorders in a monkey model of Parkinson’s disease. Sleep Med. 2015;16:1245–51.

    Article  PubMed  Google Scholar 

  86. Gutierrez-Valdez AL, Anaya-Martinez V, Ordonez-Librado JL, et al. Effect of chronic l-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis. ISRN Neurol. 2012;2012:360379.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Zaitone SA, Hammad LN, Farag NE. Antioxidant potential of melatonin enhances the response to l-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Pharmacol Rep. 2013;65:1213–26.

    Article  CAS  PubMed  Google Scholar 

  88. Naskar A, Manivasagam T, Chakraborty J, et al. Melatonin synergizes with low doses of l-dopa to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res. 2013;55:304–12.

    Article  CAS  PubMed  Google Scholar 

  89. Patki G, Lau YS. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson’s disease. Pharmacol Biochem Behav. 2011;99:704–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Yildirim FB, Ozsoy O, Tanriover G, et al. Mechanism of the beneficial effect of melatonin in experimental Parkinson’s disease. Neurochem Int. 2014;79:1–11.

    Article  CAS  PubMed  Google Scholar 

  91. Bassani TB, Gradowski RW, Zaminelli T, et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats. Brain Res. 2014;1593:95–105.

    Article  CAS  PubMed  Google Scholar 

  92. Carriere CH, Kang NH, Niles LP. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson’s disease. Brain Res 2015.

  93. Willis GL, Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of parkinson’s disease. Physiol Behav. 1999;66:785–95.

    Article  CAS  PubMed  Google Scholar 

  94. Tapias V, Cannon JR, Greenamyre JT. Melatonin treatment potentiates neurodegeneration in a rat rotenone parkinson’s disease model. J Neurosci Res. 2010;88:420–7.

    Article  CAS  PubMed  Google Scholar 

  95. Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005;6:459–66. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  PubMed  Google Scholar 

  96. Medeiros CA, de Carvalhedo Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254:459–64. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  CAS  PubMed  Google Scholar 

  97. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42–80.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19:591–6. A randomized controlled trial of melatonin in neurodegenerative disease.

    Article  PubMed  Google Scholar 

  99. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281–4.

    Article  PubMed  Google Scholar 

  100. Lauterbach EC, Victoroff J, Coburn KL, et al. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatr Clin Neurosci. 2010;22:8–18.

    Article  CAS  Google Scholar 

  101. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487–504.

    PubMed  PubMed Central  Google Scholar 

  102. Wu YH, Zhou JN, Van Heerikhuize J, et al. Decreased mt1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol Aging. 2007;28:1239–47.

    Article  CAS  PubMed  Google Scholar 

  103. Obayashi K, Saeki K, Iwamoto J, et al. Physiological levels of melatonin relate to cognitive function and depressive symptoms: The heijo-kyo cohort. J Clin Endocrinol Metab. 2015;100:3090–6.

    Article  CAS  PubMed  Google Scholar 

  104. Avila A, Cardona X, Martin-Baranera M, et al. Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction. J Clin Psychopharmacol. 2015;35:719–23.

    Article  CAS  PubMed  Google Scholar 

  105. Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatr. 2014;71:397–403.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Emory University School of Medicine, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA

    Lynn Marie Trotti

  2. Emory Sleep Center, Emory University School of Medicine, Atlanta, GA, USA

    Lynn Marie Trotti & Elias G. Karroum

Authors
  1. Lynn Marie Trotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elias G. Karroum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynn Marie Trotti.

Ethics declarations

Conflict of Interest

Elias G. Karroum declares no conflict of interest.

Lynn Marie Trotti serves as an unpaid sub-investigator on a grant from Jazz Pharmaceuticals to her institution.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Sleep

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trotti, L.M., Karroum, E.G. Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases. Curr Neurol Neurosci Rep 16, 63 (2016). https://doi.org/10.1007/s11910-016-0664-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-016-0664-3

Keywords

Search

Navigation